Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Aprogenex

This article was originally published in The Gray Sheet

Executive Summary

Aprogenex: Nets approximately $4.5 mil. through two private offerings. The Houston-based developer of the GenSite prenatal genetic testing assay announced May 31 that it had closed an offering of convertible preferred stock, netting about $4 mil. According to a recent Aprogenex SEC filing, funds from the preferred stock offering will be used for "normal operating requirements and product development costs." In mid May, Aprogenex raised $550,000 in net proceeds from the sale to "seven purchasers" of 144,300 shares of common stock and 28,860 warrants to buy common stock. The securities in the $550,000 offering were sold in units for $4.50, each unit consisting of one common share and one-fifth of a warrant to buy a common share for $7.25 by March 31, 1997...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004200

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel